вторник, 14 июня 2016 г.

Mesoblast regains full rights to stem cell heart failure treatment

Mesoblast regains full rights to stem cell heart failure treatment


REUTERS: Mesoblast Ltd on Monday said it had regained full rights to its experimental stem cell therapy for advanced chronic heart failure, which is currently in late stage testing, from Teva Pharmaceutical Industries. While Teva returned its rights to the potential blockbuster treatment without any financial payment, the Israel-based generic drugmaker can still benefit from any eventual success as one of Mesoblast's top shareholders.



from Biotech News